Catalent Stock Performance
| CTLT Stock | USD 63.48 0.01 0.02% |
Catalent has a performance score of 12 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0081, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Catalent are expected to decrease at a much lower rate. During the bear market, Catalent is likely to outperform the market. Catalent right now shows a risk of 0.64%. Please confirm Catalent value at risk, as well as the relationship between the skewness and day median price , to decide if Catalent will be following its price patterns.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Catalent are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable essential indicators, Catalent is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
Year To Date Return 40.91 | Ten Year Return 121.73 | All Time Return 217.56 |
1 | Disposition of 637 shares by Charles Lickfold of Catalent subject to Rule 16b-3 | 10/28/2024 |
2 | Acquisition by Jack Stahl of 4663 shares of Catalent subject to Rule 16b-3 | 10/30/2024 |
3 | Acquisition by Jonathan Arnold of tradable shares of Catalent subject to Rule 16b-3 | 11/01/2024 |
4 | STAT Pharmalittle Were reading about a weight loss pill, the FDA warning a compounder, and more | 11/04/2024 |
5 | Disposition of 2800 shares by Ryan Michelle R of Catalent at 59.7 subject to Rule 16b-3 | 11/11/2024 |
6 | JAZZ or CTLT Which Is the Better Value Stock Right Now | 11/13/2024 |
7 | Disposition of 1114 shares by Michael Grippo of Catalent subject to Rule 16b-3 | 11/18/2024 |
8 | Precision Medicine Market to grow by USD 66.2 Billion , rising chronic disease prevalence driving revenue, with AI redefining the landscape - Technavio | 12/04/2024 |
9 | State Street Corp Increases Stake in Catalent, Inc. | 12/10/2024 |
10 | Neo Ivy Capital Management Takes 1.08 Million Position in Catalent, Inc. | 12/12/2024 |
11 | STAT Pharmalittle Were reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more | 12/16/2024 |
12 | NVO to Invest 1.2B in New Rare Disease Drugs Facility in Denmark | 12/17/2024 |
| Begin Period Cash Flow | 280 M |
Catalent |
Catalent Relative Risk vs. Return Landscape
If you would invest 5,975 in Catalent on September 23, 2024 and sell it today you would earn a total of 373.00 from holding Catalent or generate 6.24% return on investment over 90 days. Catalent is currently generating 0.0997% in daily expected returns and assumes 0.644% risk (volatility on return distribution) over the 90 days horizon. In different words, 5% of stocks are less volatile than Catalent, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Catalent Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalent's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Catalent, and traders can use it to determine the average amount a Catalent's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1549
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | CTLT | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 0.64 actual daily | 5 95% of assets are more volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average Catalent is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Catalent by adding it to a well-diversified portfolio.
Catalent Fundamentals Growth
Catalent Stock prices reflect investors' perceptions of the future prospects and financial health of Catalent, and Catalent fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Catalent Stock performance.
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0018 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 16.13 B | ||||
| Shares Outstanding | 181.51 M | ||||
| Price To Earning | 17.80 X | ||||
| Price To Book | 3.25 X | ||||
| Price To Sales | 2.61 X | ||||
| Revenue | 4.38 B | ||||
| Gross Profit | 1.04 B | ||||
| EBITDA | (284 M) | ||||
| Net Income | (1.04 B) | ||||
| Cash And Equivalents | 345 M | ||||
| Cash Per Share | 1.92 X | ||||
| Total Debt | 4.92 B | ||||
| Debt To Equity | 0.90 % | ||||
| Current Ratio | 2.86 X | ||||
| Book Value Per Share | 19.52 X | ||||
| Cash Flow From Operations | 268 M | ||||
| Earnings Per Share | (2.28) X | ||||
| Market Capitalization | 11.52 B | ||||
| Total Asset | 9.75 B | ||||
| Retained Earnings | (781 M) | ||||
| Working Capital | 1.57 B | ||||
| Current Asset | 790.2 M | ||||
| Current Liabilities | 391.2 M | ||||
About Catalent Performance
Assessing Catalent's fundamental ratios provides investors with valuable insights into Catalent's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Catalent is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 61.12 | 44.06 | |
| Return On Tangible Assets | (0.16) | (0.15) | |
| Return On Capital Employed | (0.09) | (0.08) | |
| Return On Assets | (0.11) | (0.10) | |
| Return On Equity | (0.29) | (0.27) |
Things to note about Catalent performance evaluation
Checking the ongoing alerts about Catalent for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Catalent help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 4.38 B. Net Loss for the year was (1.04 B) with profit before overhead, payroll, taxes, and interest of 1.04 B. | |
| Catalent has a strong financial position based on the latest SEC filings | |
| Over 88.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: NVO to Invest 1.2B in New Rare Disease Drugs Facility in Denmark |
- Analyzing Catalent's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Catalent's stock is overvalued or undervalued compared to its peers.
- Examining Catalent's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Catalent's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Catalent's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Catalent's stock. These opinions can provide insight into Catalent's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.